Literature DB >> 25651424

Socioeconomic status is independently associated with overall survival in patients with multiple myeloma.

Mark A Fiala1, Joseph D Finney1, Jingxia Liu2, Keith E Stockerl-Goldstein1, Michael H Tomasson1, Ravi Vij1, Tanya M Wildes1.   

Abstract

Population-based studies suggest that black patients with multiple myeloma (MM) have a higher mortality rate than white patients. However, other studies suggest that this disparity is related to socioeconomic status (SES) rather than race. To provide clarity on this topic, we reviewed 562 patients diagnosed with MM at our institution. Patients with high SES had a median overall survival (OS) of 62.8 months (95% confidence interval [CI] 43.1-82.6 months), compared to 53.7 months (45.2-62.3 months) and 48.6 months (40.4-56.8 months) for middle and low SES, respectively (p = 0.015). After controlling for race, age, year of diagnosis, severity of comorbidities, stem cell transplant utilization and insurance provider, patients with low SES had a 54% increase in mortality rate relative to patients with high SES. To support our findings, we performed a similar analysis of 45,505 patients with MM from the Surveillance, Epidemiology and End Results-18 (SEER) database. Low SES is independently associated with poorer OS in MM.

Entities:  

Keywords:  Multiple myeloma; cancer health disparities; race; socioeconomic status

Mesh:

Year:  2015        PMID: 25651424      PMCID: PMC4831207          DOI: 10.3109/10428194.2015.1011156

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  25 in total

1.  Socioeconomic status and multiple myeloma among US blacks and whites.

Authors:  D Baris; L M Brown; D T Silverman; R Hayes; R N Hoover; G M Swanson; M Dosemeci; A G Schwartz; J M Liff; J B Schoenberg; L M Pottern; J Lubin; R S Greenberg; J F Fraumeni
Journal:  Am J Public Health       Date:  2000-08       Impact factor: 9.308

2.  The role of National Cancer Institute-designated cancer center status: observed variation in surgical care depends on the level of evidence.

Authors:  Haejin In; Bridget A Neville; Stuart R Lipsitz; Katherine A Corso; Jane C Weeks; Caprice C Greenberg
Journal:  Ann Surg       Date:  2012-05       Impact factor: 12.969

3.  Trends in the incidence and survival of multiple myeloma in South East England 1985-2004.

Authors:  Christine Renshaw; Nicolas Ketley; Henrik Møller; Elizabeth A Davies
Journal:  BMC Cancer       Date:  2010-03-01       Impact factor: 4.430

4.  Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden.

Authors:  Sigurdur Yngvi Kristinsson; Asa Rangert Derolf; Gustaf Edgren; Paul W Dickman; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

5.  Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival.

Authors:  Ahmedin Jemal; Limin X Clegg; Elizabeth Ward; Lynn A G Ries; Xiaocheng Wu; Patricia M Jamison; Phyllis A Wingo; Holly L Howe; Robert N Anderson; Brenda K Edwards
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

6.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

7.  Disentangling the effects of race/ethnicity and socioeconomic status of neighborhood in cancer stage distribution in New York City.

Authors:  Farhad Islami; Amy R Kahn; Nina A Bickell; Maria J Schymura; Paolo Boffetta
Journal:  Cancer Causes Control       Date:  2013-03-16       Impact factor: 2.506

Review 8.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.

Authors:  R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2008-10-30       Impact factor: 11.528

9.  Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study.

Authors:  Limin X Clegg; Marsha E Reichman; Barry A Miller; Benjamin F Hankey; Gopal K Singh; Yi Dan Lin; Marc T Goodman; Charles F Lynch; Stephen M Schwartz; Vivien W Chen; Leslie Bernstein; Scarlett L Gomez; John J Graff; Charles C Lin; Norman J Johnson; Brenda K Edwards
Journal:  Cancer Causes Control       Date:  2008-11-12       Impact factor: 2.506

Review 10.  Low socioeconomic status is associated with worse survival in children with cancer: a systematic review.

Authors:  Sumit Gupta; Marta Wilejto; Jason D Pole; Astrid Guttmann; Lillian Sung
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

View more
  13 in total

1.  Racial disparities in treatment use for multiple myeloma.

Authors:  Mark A Fiala; Tanya M Wildes
Journal:  Cancer       Date:  2017-01-13       Impact factor: 6.860

2.  Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race/ethnicity.

Authors:  Maira A Castañeda-Avila; Bill M Jesdale; Ariel Beccia; Ganga S Bey; Mara M Epstein
Journal:  Cancer Causes Control       Date:  2021-06-05       Impact factor: 2.506

Review 3.  Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

Authors:  Sikander Ailawadhi; Kirtipal Bhatia; Sonikpreet Aulakh; Zahara Meghji; Asher Chanan-Khan
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

4.  Are there disparities in the presentation, treatment and outcomes of patients diagnosed with medullary thyroid cancer?-An analysis of 634 patients from the California Cancer Registry.

Authors:  Christine Cox; Yingjia Chen; Rosemary Cress; Alison M Semrad; Thomas Semrad; Jessica E Gosnell; Michael J Campbell
Journal:  Gland Surg       Date:  2016-08

5.  Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.

Authors:  Jennifer M Knight; Karen L Syrjala; Navneet S Majhail; Michael Martens; Jennifer Le-Rademacher; Brent R Logan; Stephanie J Lee; Paul B Jacobsen; William A Wood; Heather S L Jim; John R Wingard; Mary M Horowitz; Muneer H Abidi; Mingwei Fei; Laura Rawls; J Douglas Rizzo
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-23       Impact factor: 5.742

6.  Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.

Authors:  S Hong; L Rybicki; D M Abounader; B J Bolwell; R Dean; A T Gerds; B K Hamilton; B T Hill; D Jagadeesh; M Kalaycio; H D Liu; B Pohlman; R Sobecks; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

7.  Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019.

Authors:  Linghui Zhou; Qin Yu; Guoqing Wei; Linqin Wang; Yue Huang; Kejia Hu; Yongxian Hu; He Huang
Journal:  BMC Cancer       Date:  2021-05-25       Impact factor: 4.430

8.  Marital Status and Survival of Patients with Chondrosarcoma: A Population-Based Analysis.

Authors:  Zhongyang Gao; Fenggang Ren; Hui Song; Yiqun Wang; Yibin Wang; Zhengchao Gao; Junjie Zhu; Xijing He
Journal:  Med Sci Monit       Date:  2018-09-20

Review 9.  Socioeconomic Status is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients: Synthesis of Studies and Review of the Literature.

Authors:  Stergios Intzes; Marianthi Symeonidou; Konstantinos Zagoridis; Zoe Bezirgianidou; Georgios Vrachiolias; Athina Spanoudaki; Emmanouil Spanoudakis
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-01-01       Impact factor: 2.576

10.  Education level as a predictor of survival in patients with multiple myeloma.

Authors:  Limei Xu; Xiuju Wang; Xueyi Pan; Xiaotao Wang; Qing Wang; Bingyi Wu; Jiahui Cai; Ying Zhao; Lijuan Chen; Wuping Li; Juan Li
Journal:  BMC Cancer       Date:  2020-08-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.